IL2 and acute myeloid leukemia: A preferential clinical benefit of HDC/LD-IL-2 was observed in patients < 60 years old having achieved CR1 after one course of induction (“chemosensitive AML”, HR 0.46, p < 0.001) (Figure 1 and Table 1).